{
  "denotations": [
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 36,
        "end": 46
      }
    },
    {
      "id": "T2",
      "obj": "Disease",
      "span": {
        "begin": 86,
        "end": 112
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 71,
        "end": 74
      }
    },
    {
      "id": "T4",
      "obj": "Disease",
      "span": {
        "begin": 115,
        "end": 120
      }
    },
    {
      "id": "T6",
      "obj": "Disease",
      "span": {
        "begin": 71,
        "end": 122
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "21623265_3",
  "text": "Currently , clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer ( NSCLC ) ."
}
